Oxford BioDynamics
Plc
("OBD" or the
"Company" and, together
with its subsidiaries, the "Group")
Notice of
Results
Oxford, UK - 21 February 2025 - Oxford BioDynamics Plc (AIM: OBD,
the Company), a precision clinical
diagnostics company bringing specific and sensitive tests to the
practice of medicine based on its EpiSwitch® 3D genomics
platform, expects to announce its
results for the year ended 30 September 2024 on Friday 28 February
2025.
-Ends-
For further details
please contact:
|
Oxford BioDynamics
Plc
Iain Ross, Executive Chairman
Paul Stockdale, CFO
|
+44 (0)1865 518910
|
|
Shore Capital -
Nominated Adviser and Joint Broker
Advisory: Stephane Auton / Lucy Bowden
Broking: Fiona Conroy
|
+44 (0)20 7408 4090
|
|
OAK Securities
- Joint Broker
Jerry Keen / Henry Clarke / Damion Carruel
|
+44 (0)203 973 3678
|
|
WG Partners - Joint
Broker
David Wilson / Claes Spång / Satheesh Nadarajah
/ Erland Sternby
|
+44 (0)20 3705 9330
|
|
Vigo Consulting -
Media / Analyst enquiries for OBD
Rozi Morris
|
+44 (0)20 7390 0230
obd@vigoconsulting.com
|
Notes to
Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM:
OBD) is an international biotechnology
company, advancing personalized healthcare by developing and
commercializing precision clinical diagnostic tests for
life-changing diseases.
Currently OBD has two commercially available
products: the EpiSwitch®
PSE (EpiSwitch Prostate Screening test) and EpiSwitch®
CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts
the predictive accuracy of a PSA test from 55% to 94% when testing
the presence or absence of prostate cancer. CiRT is a highly accurate (85%)
predictive response test to immuno-oncology checkpoint inhibitor
treatments.
The tests are based on OBD's
proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring
of biomarkers to diagnose patients or determine how individuals
might respond to a disease or treatment.
OBD's clinical smart tests have the
potential to be used across a broader range of indications, and new
tests are being developed in the areas of oncology, neurology,
inflammation, hepatology and animal health.
The Group's headquarters
and UK laboratories are in Oxford, UK. Its US operations
and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock
Exchange's AIM (LSE: OBD). For more information, please visit the
Company's website, www.oxfordbiodynamics.com,
X (@OxBioDynamics) or LinkedIn.
